Referințe 2018-03-07T17:30:26+00:00

[1] Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd edition. Geneva: World Health Organization; 2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK269619/. Data accesării: 15 sept 2016

[2] Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Chapter 11, Human Papillomavirus Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015. Disponibil la: http://www.cdc.gov/vaccines/pubs/pinkbook/index.html

[3] Weaver J Am, Epidemiology and Natural History of Genital Human Papillomavirus Infection, Osteopath Assoc 2006: p. S2;

[4] AACR CANCER PROGRESS REPORT 2017. Disponibil la: http://www.cancerprogressreport.org/Documents/AACR_CPR17_Final.pdf

[5] Forman D, de MC, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl 5:F12-F23

[6] Hartwig et al. Infectious Agents and Cancer (2017), Annex Cancer Country Tables

[7] International Agency for Research on Cancer (IARC), ”IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses”. Vol 90. Lyon, France: IARC Press; 2007.

[8] Lenselink CH, Melchers WJG, Quint WGV, Hoebers AMJ, Hendriks JCM, et al. (2008) Sexual Behaviour and HPV Infections in 18 to 29 Year Old Women in the Pre-Vaccine Era in the Netherlands. PLoS ONE 3(11): e3743. doi:10.1371/journal.pone.0003743

[9] American Cancer Society, What is cervical cancer?, Disponibil la: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-what-is-cervical-cancer

[10] Bruni L, et al.,” ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Romania”. Summary Report 2016-02-26

[11] Castellsagué X, et al, ”HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives”, Gynecol Oncol (2009), doi:10.1016/j.ygyno.2009.09.021.

[12] de Sanjose S, Quint WGV, Alemany L, et al.” Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study”. Lancet Oncol. 2010;11(11):1048–1056.

[13] Susan Hariri, et al., ”Vaccine- Preventable Diseases Surveillance Manual”, 5th Edition, 2011, Human Papillomavirus, Chapter 5-1., Disponibil la: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.pdf.

[14] Winer, Rachel L. et al. “Risk of Female Human Papillomavirus Acquisition Associated with First Male Sex Partner.” The Journal of infectious diseases 197.2 (2008): 279–282. PMC. Web.

[15] American Cancer Society ”What are the risk factors for cervical cancer?”, Disponibil la: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-risk-factors.

[16] Arbyn, M. et al. “European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document.” Annals of Oncology 21.3 (2010): 448–458. PMC. Web.

[17] Ministerul Sănătății-Ordin nr. 377/2017 aprobarea Normelor tehnice de realizare a programelor naţionale de sănătate publică pentru anii 2017 şi 2018

[18] Lawrence von Karsa et al., European guidelines for quality assurance in cervical cancer screening, Second edition – Supplements, Luxembourg: Publications Office of the European Union, 2015

[19] American Cancer Society, The HPV DNA test, http://www.cancer.org/cancer/cervicalcancer/moreinformation/cervicalcancerpreventionandearlydetection/cervical-cancer-prevention-and-early-detection-h-p-v-test

[20] Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: followup of four European randomised controlled trials. Lancet. 2014;383(9916):524–532

[21] Wagner, Monika et al. “Global Availability of Data on HPV Genotype-Distribution in Cervical, Vulvar and Vaginal Disease and Genotype-Specific Prevalence and Incidence of HPV Infection in Females.” Infectious Agents and Cancer 10 (2015): 13. PMC. Web.

[22] Gardasil 9- Anexa 1. Rezumatul Caracteristicilor produsului, Disponibil la: https://ec.europa.eu/health/documents/community-register/2015/20150610131761/anx_131761_ro.pdf.

[23] World Health Organization- Position Paper on HPV Vaccines, Disponibil la: http://www.who.int/immunization/position_papers/pp_hpv_oct2014_presentation.pdf

[24] Manhart, Lisa E. PhD*; Holmes, King K. MD, PhD*; Koutsky, Laura A. PhD*§; Wood, Troy R. BS‡§; Kenney, Donna L. BA‡§; Feng, Qinghua PhD‡§; Kiviat, Nancy B. MD‡§ Human Papillomavirus Infection Among Sexually Active Young Women in the United States: Implications for Developing a Vaccination Strategy, Sexually Transmitted Diseases: August 2006 – Volume 33 – Issue 8 – pp 502-508

[25] Gardasil 9- Summary of Product Info, Disponibil la: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003852/WC500189111.pdf

[26] Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. The Lancet Infectious diseases. 2015;15(5):565-580. doi:10.1016/S1473-3099(14)71073-4.

[27] Baldur-Felskov B et al. J Natl Cancer Inst. 2014;106:djt460.

[28] Garland SM, Kjaer SK, Muñoz N, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2016;63(4):519-527. doi:10.1093/cid/ciw354.

[29] World Health Organization- HPV vaccination of males to reduce incidence of cervical cancer in females, Disponibil la: http://www.who.int/immunization/position_papers/hpv_grad_male_vaccination.pdf?ua=1